Dimension Therapeutics

General Information

We are a leading gene therapy platform company focused on discovering and developing new therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. Our initial programs address hemophilia B, hemophilia A, ornithine transcarbamylase, or OTC, deficiency, and glycogen storage disease type Ia, or GSDIa. In August 2015, we submitted an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or FDA, for our lead product candidate, DTX101 for the treatment of hemophilia B. In September 2015, we received notification allowing us to proceed with our Phase I/II clinical trial of DTX101. DTX101 was also granted Orphan Drug Designation in the United States in August 2015 and Fast Track Designation in September 2015 for the treatment of hemophilia B. We plan to initiate clinical trials for DTX101 by the end of 2015. We retain the global rights to all of our programs, with the exception of our hemophilia A program, which is partnered with Bayer HealthCare LLC, or Bayer.

Employees: 49
Founded: 2013
Contact Information
Address 840 Memorial Drive, Cambridge, MA 02139, US
Phone Number (617) 401-0011
Web Address http://www.dimensiontx.com
View Prospectus: Dimension Therapeutics
Financial Information
Market Cap $323.4mil
Revenues $5.9 mil (last 12 months)
Net Income $-22.5 mil (last 12 months)
IPO Profile
Symbol DMTX
Exchange NASDAQ
Shares (millions): 5.5
Price range $13.00 - $13.00
Est. $ Volume $71.5 mil
Manager / Joint Managers Goldman Sachs/ Citigroup/ Wells Fargo Securities
CO-Managers Canaccord Genuity/ Cantor Fitzgerald
Expected To Trade: 10/22/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change